Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | VHL | P40337 | 1/20 | 0.39 |
| ▸ | ELOC | Q15369 | 1/20 | 0.39 |
| ▸ | ELOB | Q15370 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9444146 | 0.71 | ALDH1A1 (0.35) | GAAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL13811347 | 0.68 | ALDH1A1 (0.42) | GAAMAPTKDM4EMEN1RECQL | |
| SCHEMBL1520640 | 0.67 | ALDH1A1 (0.61) | GAAMAPTKDM4EMEN1RECQL | |
| SCHEMBL6967710 | 0.66 | CA1 (0.36) | — | |
| SCHEMBL13692142 | 0.65 | ALDH1A1 (0.59) | GAAMAPTKDM4EMEN1RECQL | |
| SCHEMBL12270193 | 0.65 | ALDH1A1 (0.47) | GAAMAPTKDM4EMEN1RECQL | |
| SCHEMBL2690986 | 0.64 | — | — | |
| SCHEMBL5105458 | 0.64 | — | — | |
| SCHEMBL9667159 | 0.64 | KDM4E (0.46) | GAAMAPTKDM4EKMT2AALDH1A1 | |
| SCHEMBL25496326 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| CN-100451016-C | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2009-01-14 | — | — | CN | disclosed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| CN-1876648-A | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2006-12-13 | — | — | CN | disclosed |
| CN-1267424-C | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | BIOVITRUM AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| CN-1479727-A | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-03-03 | — | — | CN | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | GAA 844/4885MAPT 3977/4885KDM4E 1971/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | GAA 844/4885MAPT 3977/4885KDM4E 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.